Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Sep 4;2014(9):CD006647.
doi: 10.1002/14651858.CD006647.pub4.

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

Elvira C van Dalen  1 , Martine F Raphaël, Huib N Caron, Leontien C M Kremer
Affiliations
Meta-Analysis

Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer

Elvira C van Dalen et al. Cochrane Database Syst Rev. .

Abstract

Background: One of the most important adverse effects of anthracyclines is cardiotoxicity. A well-informed decision on the use of anthracyclines in the treatment of childhood cancers should be based on evidence regarding both antitumour efficacy and cardiotoxicity. This review is the second update of a previously published Cochrane review.

Objectives: To compare antitumour efficacy (survival and tumour response) and cardiotoxicity of treatment including or not including anthracyclines in children with childhood cancer.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 6), MEDLINE (1966 to July 2013) and EMBASE (1980 to July 2013). In addition, we searched reference lists of relevant articles and conference proceedings, the International Society for Paediatric Oncology (SIOP) (from 2002 to 2012) and American Society of Clinical Oncology (ASCO) (from 2002 to 2013). We have searched for ongoing trials in the ISRCTN register and the National Institute of Health register (both screened August 2013) (http://www.controlled-trials.com).

Selection criteria: Randomised controlled trials (RCTs) comparing treatment of any type of childhood cancer with and without anthracyclines and reporting outcomes concerning antitumour efficacy or cardiotoxicity.

Data collection and analysis: Two review authors independently performed the study selection, risk of bias assessment and data extraction. Analyses were performed according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions.

Main results: We identified RCTs for seven types of tumour, acute lymphoblastic leukaemia (ALL) (three trials; 912 children), Wilms' tumour (one trial; 316 children), rhabdomyosarcoma and undifferentiated sarcoma (one trial; 413 children), Ewing's sarcoma (one trial; 94 children), non-Hodgkin lymphoma (one trial; 284 children), hepatoblastoma (one trial; 255 children) and acute myeloid leukaemia (AML) (one trial; 394 children). All studies had methodological limitations. For ALL no evidence of a significant difference in antitumour efficacy was identified in the meta-analyses, but in most individual studies there was a suggestion of better antitumour efficacy in patients treated with anthracyclines. For both Wilms' tumour and Ewing's sarcoma a significant difference in event-free and overall survival in favour of treatment with anthracyclines was identified, although for Wilms' tumour the significant difference in overall survival disappeared with long-term follow-up. For rhabdomyosarcoma and undifferentiated sarcoma, non-Hodgkin lymphoma and hepatoblastoma no difference in antitumour efficacy between the treatment groups was identified. The same was true for AML, with the exception of overall survival in a post hoc analysis in a subgroup of patients with relapsed core binding factor (CBF)-AML in which patients treated with anthracyclines did better. Clinical cardiotoxicity was evaluated in four RCTs; no significant difference between the treatment groups was identified, but in all individual studies there was a suggestion of a lower rate of clinical cardiotoxicity in patients who did not receive anthracyclines. None of the studies evaluated asymptomatic cardiac dysfunction. No RCTs were identified for other childhood cancers.

Authors' conclusions: At the moment no evidence from RCTs is available which underscores the use of anthracyclines in ALL. However, 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. For Wilms' tumour, rhabdomyosarcoma and undifferentiated sarcoma, Ewing's sarcoma, non-Hodgkin lymphoma, hepatoblastoma and AML only one RCT was available for each type and, therefore, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours. For other childhood cancers no RCTs were identified and therefore no conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
2
2
Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analyses).
3
3
Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses).
4
4
Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analyses).
5
5
Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the analyses).
6
6
Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.3 Tumour response.
7
7
Forest plot of comparison: 1 No anthracyclines versus anthracyclines, outcome: 1.4 Clinical cardiotoxicity.
1.1
1.1. Analysis
Comparison 1 No anthracyclines versus anthracyclines, Outcome 1 Overall survival (Parmar's method was used to obtain the necessary data for the meta‐analysis).
1.2
1.2. Analysis
Comparison 1 No anthracyclines versus anthracyclines, Outcome 2 Event‐free survival (Parmar's method was used to obtain the necessary data for the meta‐analysis).
1.3
1.3. Analysis
Comparison 1 No anthracyclines versus anthracyclines, Outcome 3 Tumour response.
1.4
1.4. Analysis
Comparison 1 No anthracyclines versus anthracyclines, Outcome 4 Clinical cardiotoxicity.
1.5
1.5. Analysis
Comparison 1 No anthracyclines versus anthracyclines, Outcome 5 Overall survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis).
1.6
1.6. Analysis
Comparison 1 No anthracyclines versus anthracyclines, Outcome 6 Event‐free survival Wilms' tumour long‐term follow‐up (Parmar's method was used to obtain the necessary data for the meta‐analysis).
See this image and copyright information in PMC

Update of

References

References to studies included in this review

D'Angio 1981 {published data only}
    1. D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302‐11. - PubMed
D'Angio 1981 II‐III FH {published data only}
    1. D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302‐11. - PubMed
D'Angio 1981 II‐III FH UH {published data only}
    1. D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302‐11. - PubMed
    1. Green DM. The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology 2004;22:1366‐72. - PubMed
D'Angio 1981 II‐III UH {published data only}
    1. D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302‐11. - PubMed
D'Angio 1981 IV {published data only}
    1. D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer 1981;47:2302‐11. - PubMed
    1. Green DM. The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology 2004;22:1366‐72. - PubMed
Eden 1991 {published data only}
    1. Eden OB, Lilleyman JS, Richards S, Shaw MP, Peto J. Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). British Journal of Haematology 1991;78:187‐96. - PubMed
Kaspers 2013 {published data only}
    1. Kaspers GJ, Zimmermann M, Reinhardt D, Gibson BE, Tamminga RY, Aleinikova O, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. Journal of Clinical Oncology 2013;31(5):599‐607. - PubMed
Maurer 1988 {published data only}
    1. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer 1988;61:209‐20. - PubMed
Maurer 1988 Group 3 {published data only}
    1. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer 1988;61:209‐20. - PubMed
Maurer 1988 Group 4 {published data only}
    1. Maurer HM, Beltangady M, Gehan EA, Crist W, Hammond D, Hays DM, et al. The Intergroup Rhabdomyosarcoma Study‐I. A final report. Cancer 1988;61:209‐20. - PubMed
Nesbit 1990 {published data only}
    1. Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long‐term follow‐up of the First Intergroup study. Journal of Clinical Oncology 1990;8:1664‐74. - PubMed
Perilongo 2009 {published data only}
    1. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard‐risk hepatoblastoma. The New England Journal of Medicine 2009;361:1662‐70. - PubMed
Sposto 2001 {published data only}
    1. Sposto R, Meadows AT, Chilcote RR, Steinherz PG, Kjeldsberg C, Kadin ME, et al. Comparison of long‐term outcome of children and adolescents with disseminated non‐lymphoblastic non‐Hodgkin lymphoma treated with COMP or daunomycin‐COMP: A report from the Children's Cancer Group. Medical and Pediatric Oncology 2001;37:432‐41. - PubMed
Van der Does 1975 {published data only}
    1. Does‐van den Berg A, Koning J, Reerink H, Vries JA, Zanen GE. Acute lymphatic leukemia in children in the Netherlands; study ALL I, 1972‐1973; Dutch Childhood Leukemia Study Group [Acute lymfatische leukemie bij kinderen in Nederland; onderzoek ALL I, 1972‐1973; Stichting Nederlandse Werkgroep Leukemie bij Kinderen (SNWLK)]. Nederlands Tijdschrift voor Geneeskunde 1975;119:1445‐51. - PubMed
Van der Does 1989 {published data only}
    1. Does‐van den Berg A, Wering ER, Suciu S, Solbu G, 't Veer MB, Rammeloo JA, et al. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L‐asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). The American Journal of Pediatric Hematology/Oncology 1989;11:125‐33. - PubMed

References to studies excluded from this review

Alvegard 1989a {published data only}
    1. Alvegard TA, Sigurdsson H, Mouridsen H, Solheim O, Unsgaard B, Ringborg U, et al. Adjuvant chemotherapy with doxorubicin in high‐grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. Journal of Clinical Oncology 1989;7:1504‐13. - PubMed
Alvegard 1989b {published data only}
    1. Alvegard TA, Berg NO, Ranstam J, Rydholm A, Rooser B. Prognosis in high‐grade soft tissue sarcomas. The Scandinavian Sarcoma Group experience in a randomized adjuvant chemotherapy trial. Acta Orthopaedica Scandinavica 1989;60:517‐21. - PubMed
Alvegard 1990 {published data only}
    1. Alvegard TA, Berg NO, Baldetorp B, Ferno M, Killander D, Ranstam J, et al. Cellular DNA content and prognosis of high‐grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. Journal of Clinical Oncology 1990;8:538‐47. - PubMed
Anonymous 1987 {published data only}
    1. Anonymous. Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer. Gruppo Interegionale Cooperativo Oncologico Ginecologia. Lancet 1987;2:353‐9. - PubMed
Antillon 2008 {published data only}
    1. Antillon F, Castellanos M, Valverde P, Luna‐Fineman S, Garrido C, Serrato T, et al. Treating pediatric soft tissue sarcomas in a country with limited resources: The experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatric Blood and Cancer 2008;51:760‐4. - PubMed
Antman 1984a {published data only}
    1. Antman KH, Amato D, Lerner H, Suit H, Corson J, Wood W, et al. Pooled results of two randomized trials of adjuvant doxorubicin for sarcomas: Eastern Cooperative Oncology Group and Dana‐Farber Cancer Institute/Massachusetts General Hospital Study. In: Jones S, Salmon S editor(s). Adjuvant Therapy of Cancer IV. Orlando: Grune and Stratton, 1984:611‐20.
Antman 1984b {published data only}
    1. Antman K, Suit H, Amato D, Corson J, Wood W, Proppe K, et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. Journal of Clinical Oncology 1984;2:601‐8. - PubMed
Antman 1985 {published data only}
    1. Antman KH, Amato D, Lerner H, Suit HD, Corson J, Wood WC, et al. Adjuvant doxorubicin for sarcoma: data from the ECOG and DFCI/MGH studies. Cancer Treatment Symposia 1985;3:109‐15.
Antman 1987 {published data only}
    1. Antman K, Amato D, Pilepich M, Lerner H, Balcerzak S, Borden E, et al. A preliminary analysis of a randomized intergroup (SWOG, ECOG, CALGB, NCOG) trial of adjuvant doxorubicin for soft tissue sarcomas. In: Salmon S editor(s). Adjuvant Therapy of Cancer V. Orlando: Grune and Stratton, 1987:725‐34.
Antman 1990 {published data only}
    1. Antman K, Ryan I, Borden E, Wood WC, Lerner HL, Corson JM, et al. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10‐year results and review of the literature. In: Salmon S editor(s). Adjuvant Therapy of Cancer VI. Philadelphia: WB Saunders, 1990:529‐44.
Aur 1972 {published data only}
    1. Aur RJ, Verzosa MS, Hustu HO, Simone JV. Response to combination therapy after relapse in childhood acute lymphocytic leukemia. Cancer 1972;30:334‐8. - PubMed
Bacci 1989 {published data only}
    1. Bacci G, Pignatti G, Dallari D, Mercuri M, Bertoni F, Bacchini P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for telangiectatic osteogenic sarcoma of the extremities. Journal of Chemotherapy 1989;1:190‐6. - PubMed
Balwierz 2013 {published data only}
    1. Balwierz W, Pawinska‐Wasikowska K, Klelawka T, Czogala M, Matysiak M, Fic‐Sikorska B, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in Poland. Magazine of European Medical Oncology 2013;6:54‐62. - PMC - PubMed
Barr 1992 {published data only}
    1. Barr RD, DeVeber LL, Pai KM, Andrew M, Halton J, Cairney AE, et al. Management of children with acute lymphoblastic leukemia by the Dana‐Farber Cancer Institute protocols. An update of the Ontario experience. American Journal of Pediatric Hematology/Oncology 1992;14:136‐9. - PubMed
Bellani 1978 {published data only}
    1. Bellani FF, Gasparini M, Gennari L, Fontanillas L, Bonadonna G. Adjuvant treatment with adriamycin in primary operable osteosarcoma. Cancer Treatment Reports 1978;62:279‐81. - PubMed
Berman 1989 {published data only}
    1. Berman E, Raymond V, Gee T, Kempin SJ, Gulati S, Andreeff M, et al. Idarubicin in acute leukemia: results of studies at Memorial Sloan‐Kettering Cancer Center. Seminars of Oncology 1989;16:30‐4. - PubMed
Bernthal 2012 {published data only}
    1. Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, et al. Long‐term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high‐grade, operable osteosarcoma. Cancer 2012;118(23):5888‐93. - PubMed
Bessho 1994 {published data only}
    1. Bessho F, Kinumaki H, Yokota S, Hayashi Y, Kobayashi M, Kamoshita S. Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. Medical and Pediatric Oncology 1994;23:111‐5. - PubMed
Biondi 2006 {published data only}
    1. Biondi A, Rizzari C, Valsecchi MG, Lorenzo P, Arico M, Basso G, et al. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica 2006;91:534‐7. - PubMed
Birch 1986 {published data only}
    1. Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. Journal of Clinical Oncology 1986;4:400‐7. - PubMed
Blakely 2003 {published data only}
    1. Blakely ML, Shamberger RC, Norkool P, Beckwith JB, Green DM, Ritchey ML. Outcome of children with cystic partially differentiated nephroblastoma treated with or without chemotherapy. Journal of Pediatric Surgery 2003;38:897‐900. - PubMed
Bradford 1998 {published data only}
    1. Bradford WB, Jose BO, Butler D, Lindberg RD, Paris K, Spanos WJ, et al. Rhabdomyosarcoma in children‐‐a ten year review. The Journal of the Kentucky Medical Association 1998;96:399‐402. - PubMed
Breslow 2004 {published data only}
    1. Breslow NE, Ou SS, Beckwith JB, Haase GM, Kalapurakal JA, Ritchey ML, et al. Doxorubicin for favorable histology, Stage II‐III Wilms tumor: results from the National Wilms Tumor Studies. Cancer 2004;101:1072‐80. - PubMed
Brouwer 2007 {published data only}
    1. Brouwer CA, Gietema JA, Berg MP, Bink‐Boelkens MT, Elzenga NJ, Haaksma J, et al. Low‐dose anthracyclines in childhood Acute Lymphoblastic Leukemia (ALL): no cardiac deterioration more than 20 years post‐treatment. Journal of Cancer Survivorship 2007;1:255‐60. - PubMed
Burnett 2006 {published data only}
    1. Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK. Long‐term result of the MRC AML10 trial. Clinical Advances in Hematology and Oncology 2006;4:445‐51. - PubMed
Caceres 1978 {published data only}
    1. Caceres E, Zaharia M, Moran M, Tejada F. Adjuvant whole‐lung radiation with or without adriamycin treatment in osteogenic sarcoma. Cancer Treatment Reports 1978;62:297‐9. - PubMed
Canter 2007 {published data only}
    1. Canter RJ, Qin L‐X, Downey RJ, Brennan MF, Singer S, Maki RG. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft‐tissue sarcoma of the extremity: a retrospective analysis. Cancer 2007;110:2050‐60. - PubMed
Carlsen 1989 {published data only}
    1. Carlsen NL, Schroeder H, Bro PV, Hesselbjerg U, Jensen KB, Nielsen OH, et al. Response to multimodal treatment in advanced neuroblastomas. Factors associated with complete remission induction, and factors associated with prolonged survival. Anticancer Research 1989;9:837‐44. - PubMed
Castellino 2008 {published data only}
    1. Castellino SM, Alonzo TA, Buxton A, Gold S, Lange BJ, Woods WG. Outcomes in childhood AML in the absence of transplantation in first remission ‐ Children's Cancer Group (CCG) studies 2891 and CCG 213. Pediatric Blood and Cancer 2008;50:9‐16. - PubMed
Chau 2003 {published data only}
    1. Chau I, Jones R, Cunningham D, Wotherspoon A, Maisey N, Norman AR, et al. Outcome of follicular lymphoma grade 3: is anthracycline necessary as front‐line therapy?. British Journal of Cancer 2003;89:36‐42. - PMC - PubMed
Chessells 1992 {published data only}
    1. Chessells JM, Bailey CC, Richards S. MRC UKALL X. The UK protocol for childhood ALL: 1985‐1990. Leukemia 1992;6:157‐61. - PubMed
Chessells 2002 {published data only}
    1. Chessells JM, Harrison G, Richards SM, Gibson BE, Bailey CC, Hill FG, et al. Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. British Journal of Haematology 2002;118:445‐55. - PubMed
Craft 1993 {published data only}
    1. Craft AW, Burgers JM. The European Osteosarcoma Intergroup (E.O.I.) studies 1980‐1991. Cancer Treatment and Research 1993;62:279‐86. - PubMed
Creutzig 2005 {published data only}
    1. Creutzig U, Zimmermann M, Ritter J, Reinhardt D, Hermann J, Henze G, et al. Treatment strategies and long‐term results in paediatric patients treated in four consecutive AML‐BFM trials. Leukemia 2005;19:2030‐42. - PubMed
Creutzig 2006 {published data only}
    1. Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony‐stimulating factor in children and adolescents with acute myeloid leukemia: results of AML‐BFM 98. Journal of Clinical Oncology 2006;24:4499‐506. - PubMed
Crist 1995 {published data only}
    1. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. Journal of Clinical Oncology 1995;13:610‐30. - PubMed
Culbert 1991 {published data only}
    1. Culbert SJ, Shuster JJ, Land VJ, Wharam MD, Thomas PR, Nitschke R, et al. Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group study. Cancer 1991;67:37‐42. - PubMed
D'Angio 1989 {published data only}
    1. D'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, DeLorimier A, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer 1989;64:349‐60. - PubMed
De Bernardi 2003 {published data only}
    1. Bernardi B, Nicolas B, Boni L, Indolfi P, Carli M, Cordero di Montezemolo L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high‐dose protocols adopted by the Italian Co‐Operative Group for Neuroblastoma. Journal of Clinical Oncology 2003;21:1592‐601. - PubMed
De Bernardi 2009 {published data only}
    1. Bernardi B, Gerrard M, Boni L, Rubie H, Canete A, Cataldo AD, et al. Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. Journal of Clinical Oncology 2009;27:1034‐40. - PubMed
Dluzniewska 2003 {published data only}
    1. Dluzniewska A, Balwierz W, Balcerska A, Chybicka A, Dobaczewski G, Kowalczyk J, et al. Efficacy of idarubicin in the treatment of childhood acute non‐lymphoblastic leukemia: report of Polish Pediatric Leukemia/Lymphoma Study Group. Przeglad Lekarski 2003;60 Suppl 5:17‐21. - PubMed
Dobashi 2006 {published data only}
    1. Dobashi N, Yamaguchi Y, Asai O, Yano S, Osawa H, Yahagi Y, et al. Intensifying daunorubicin in induction for patients with core binding factor leukemia. International Journal of Hematology 2006;84:463‐4. - PubMed
Dunst 1998 {published data only}
    1. Dunst J. Therapy results of the British ET‐1 study for Ewing's sarcoma. Strahlentherapie und Onkologie 1998;174:289‐90. - PubMed
Eilber 1988 {published data only}
    1. Eilber FR, Giuliano AE, Huth JF, Morton DL. A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high‐grade extremity soft‐tissue sarcoma. American Journal of Clinical Oncology 1988;11:39‐45. - PubMed
Einhorn 1981 {published data only}
    1. Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. The New England Journal of Medicine 1981;305:727‐31. - PubMed
Elomaa 1993 {published data only}
    1. Elomaa I. An update of Scandinavian studies of osteosarcoma. Cancer Treatment and Research 1993;62:293‐8. - PubMed
Etcubanas 1984 {published data only}
    1. Etcubanas E, Hustu O, Sklar M, Pratt C. Influence of different treatment modalities on the curability of childhood rhabdomyosarcoma of the head or neck. European Paediatric Haematology & Oncology 1;1984:239‐44.
Evans 1985 {published data only}
    1. Evans R, Nesbit M, Askin F, Burgert O, Cangir A, Foulkes M, et al. Local recurrence, rate and sites of metastases, and time to relapse as a function of treatment regimen, size of primary and surgical history in 62 patients presenting with non‐metastatic Ewing's sarcoma of the pelvic bones. International Journal of Radiation Oncology, Biology, Physics 1985;11:129‐36. - PubMed
Evans 1991 {published data only}
    1. Evans AE, Norkool P, Evans I, Breslow N, D'Angio GJ. Late effects of treatment for Wilms' tumor. A report from the National Wilms' Tumor Study Group. Cancer 1991;67:331‐6. - PubMed
Fink 1990 {published data only}
    1. Fink FM, Gadner H, Grumayer ER, Kardos G, Revesz T, Urban C, et al. Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian‐Hungarian study AML‐IGCI‐84. Haematology and Blood Transfusion 1990;33:233‐6. - PubMed
Frappaz 2002 {published data only}
    1. Frappaz D, Perol D, Michon J, Berger C, Coze C, Bernard JL, et al. The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis. British Journal of Cancer 2002;87:1197‐203. - PMC - PubMed
Fukuoka 1994 {published data only}
    1. Fukuoka M, Masuda N, Takada M, Kodama N, Kawahara M, Furuse K. Dose‐intensive chemotherapy in extensive‐stage small cell lung cancer. Seminars in Oncology 1994;21:43‐7. - PubMed
Gallegos‐Castorena 2009 {published data only}
    1. Gallegos‐Castorena S, Medina‐Sanson A, Gonzalez‐Ramella O, Sanchez‐Zubieta F, Martinez‐Avalos A. Improved treatment results in Mexican children with acute myeloid leukemia using a Medical Research Council (MRC)‐acute myeloid leukemia 10 modified protocol. Leukemia and Lymphoma 2009;50:1132‐7. - PubMed
Garbes 1987 {published data only}
    1. Garbes ID, Gomez GA, Han T, Henderson ES. Salvage chemotherapy for advanced Hodgkin's disease. Medical and Pediatric Oncology 1987;15:45‐8. - PubMed
Gaynon 1993 {published data only}
    1. Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow‐up report of the Childrens Cancer Group Study CCG‐106. Journal of Clinical Oncology 1993;11:2234‐42. - PubMed
Gelderblom 2011 {published data only}
    1. Gelderblom H, Jinks RC, Sydes M, Bramwell VH, Glabbeke M, Grimer RJ, et al. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. European Journal of Cancer 2011;47(6):895‐902. - PubMed
Glanzmann 1998 {published data only}
    1. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiotherapy & Oncology 1998;46:51‐62. - PubMed
Green 1994 {published data only}
    1. Green DM, Breslow NE, Beckwith JB, Moksness J, Finklestein JZ, D'Angio GJ. Treatment of children with clear‐cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group. Journal of Clinical Oncology 1994;12:2132‐7. - PubMed
Green 1996 {published data only}
    1. Green DM, Breslow NE, Evans I, Moksness J, D'Angio GJ. Treatment of children with stage IV favorable histology Wilms tumor: a report from the National Wilms Tumor Study Group. Medical and Pediatric Oncology 1996;26:147‐52. - PubMed
Green 1999 {published data only}
    1. Green DM, Hyland A, Chung CS, Zevon MA, Hall BC. Cancer and cardiac mortality among 15‐year survivors of cancer diagnosed during childhood or adolescence. Journal of Clinical Oncology 1999;17:3207‐15. - PubMed
Grier 1990 {published data only}
    1. Grier HE, Gelber RD, Clavell LA, Camitta BM, Link MP, Garcea MJ, et al. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematology and Blood Transfusion 1990;33:193‐7. - PubMed
Grundy 2012 {published data only}
    1. Grundy PE, Green DM, Dirks AC, Berendt AE, Breslow NE, Anderson JR, et al. Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies‐4 and ‐5: a report from the Children's Oncology Group. Pediatric Blood and Cancer 2012;59(4):631‐5. - PMC - PubMed
Gururangan 2000 {published data only}
    1. Gururangan S, Sposto R, Cairo MS, Meadows AT, Finlay JL. Outcome of CNS disease at diagnosis in disseminated small noncleaved‐cell lymphoma and B‐cell leukemia: a Children's Cancer Group study. Journal of Clinical Oncology 2000;18:2017‐25. - PubMed
Hainsworth 1985 {published data only}
    1. Hainsworth JD, Williams SD, Einhorn LH, Birch R, Greco FA. Successful treatment of resistant germinal neoplasms with VP‐16 and cisplatin: results of a Southeastern Cancer Study Group trial. Journal of Clinical Oncology 1985;3:666‐71. - PubMed
Halazun 1974 {published data only}
    1. Halazun JF, Wagner HR, Gaeta JF, Sinks LF. Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia. Cancer 1974;33:545‐54. - PubMed
Harms 2000 {published data only}
    1. Harms D, Janka‐Schaub GE. Co‐operative study group for childhood acute lymphoblastic leukemia (COALL): long‐term follow‐up of trials 82, 85, 89 and 92. Leukemia 2000;14:2234‐9. - PubMed
Hayashi 2008 {published data only}
    1. Hayashi K, Tsuchiya H, Yamamoto N, Takeuchi A, Tomita K. Functional outcome in patients with osteosarcoma around the knee joint treated by minimised surgery. International Orthopaedics 2008;32:63‐8. - PMC - PubMed
Hays 1988 {published data only}
    1. Hays DM, Shimada H, Raney RB Jr, Tefft M, Newton W, Crist WM, et al. Clinical staging and treatment results in rhabdomyosarcoma of the female genital tract among children and adolescents. Cancer 1988;61:1893‐903. - PubMed
Henze 1989 {published data only}
    1. Henze G, Fengler R, Hartmann R, Dopfer R, Gobel U, Graf N, et al. Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia. Cancer Chemotherapy & Pharmacology 1989;24:S16‐9. - PubMed
Hitchcock‐Bryan 1986 {published data only}
    1. Hitchcock‐Bryan S, Gelber R, Cassady JR, Sallan SE. The impact of induction anthracycline on long‐term failure‐free survival in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology 1986;14:211‐5. - PubMed
Hodgson 2003 {published data only}
    1. Hodgson DC, Tsang RW, Pintilie M, Sun A, Wells W, Crump M, et al. Impact of chest wall and lung invasion on outcome of stage I‐II Hodgkin's lymphoma after combined modality therapy. International Journal of Radiation Oncology, Biology, Physics 2003;57:1374‐81. - PubMed
Holland 1971 {published data only}
    1. Holland JF. E Pluribus Unum: Presidential address. Cancer Research 1971;31:1319‐29. - PubMed
Humphrey 1975 {published data only}
    1. Humphrey GB, Fernbach DJ, Razek AA, Stuckey WJ, Komp D, George S. Evaluation of daunorubicin (NSC‐82151) and methotrexate (NSC‐740) in combination as a remission maintenance regimen in the treatment of acute leukemia. Cancer Chemotherapy Reports 1975;59:395‐9. - PubMed
Iarussi 2003 {published data only}
    1. Iarussi D, Indolfi P, Pisacane C, Casale F, Martino V, Fusco A, et al. Comparison of left ventricular function by echocardiogram in patients with Wilms' tumor treated with anthracyclines versus those not so treated. The American Journal Of Cardiology 2003;92:359‐61. - PubMed
Ihde 1977 {published data only}
    1. Ihde DC, Kane RC, Cohen MH, McIntire KR, Minna JD. Adriamycin therapy in American patients with hepatocellular carcinoma. Cancer Treatment Report 1977;61:1385‐7. - PubMed
Isu 1992 {published data only}
    1. Isu K, Yamawaki S, Usui M. A group study of neoadjuvant chemotherapy for osteosarcoma ‐ Results and problems of T‐12 protocol. Journal of the Japanese Orthopaedic Association 1992;66:S9‐S10.
Iwenofu 2008 {published data only}
    1. Iwenofu OH, Lackman RD, Staddon AP, Goodwin DG, Haupt HM, Brooks JS. Phospho‐S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Modern Pathology 2008;21:231‐7. - PubMed
Jaffe 1981 {published data only}
    1. Jaffe N, Link MP, Cohen D, Traggis D, Frei E III, Watts H, et al. High‐dose methotrexate in osteogenic sarcoma. National Cancer Institute Monograph 1981:201‐6. - PubMed
Janka‐Schaub 1988 {published data only}
    1. Janka‐Schaub GE, Winkler K, Gobel U, Graubner U, Schwenger M, Haas RJ, et al. First results of the CO ALL‐85 cooperative study for high‐risk patients with acute lymphatic leukemia. Klinische Padiatrie 1988;200:171‐6. - PubMed
Kalapurakal 2010 {published data only}
    1. Kalapurakal JA, Li SM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, et al. Intraoperative spillage of favorable histology Wilms tumor cells: influence of irradiation and chemotherapy regimens on abdominal recurrence. A report from the National Wilms Tumor Study Group. International Journal of Radiation Oncology, Biology, Physics 2010;76:201‐6. - PMC - PubMed
Karachunskii 2007 {published data only}
    1. Karachunskii AI, Miakova NV, Rumiantseva I, Timakov AM, Makhortykh TZ, Fechina LG, et al. The results of a multicenter trial of acute lymphoblastic leukemia treatment on ALL‐MB 91/ALL‐BFM 90m in children: analysis of efficacy and toxicity. Terapevticheskii Arkhiv 2007;79:19‐26. - PubMed
Karachunskiy 2008 {published data only}
    1. Karachunskiy A, Herold R, Stackelberg A, Miakova N, Timakow A, Mahortih T, et al. Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia. Leukemia 2008;22:1144‐53. - PubMed
Kaspers 2010 {published data only}
    1. Kaspers G, Zimmermann M, Reinhardt D, Gibson B, Tamminga R, Aleinikova O, et al. Central Nervous System (CNS) involvement in pediatric relapsed acute myeloid leukemia: Results and lessons from study relapsed AML 2001/01. Blood (Annual Meeting of the American Society of Hematology). 2010:116 (abstract 184).
Kazanowska 2006 {published data only}
    1. Kazanowska B, Reich A, Wrobel G, Balcerska A, Balwierz W, Bodalski J, et al. Metastatic soft tissue sarcomas in children ‐ A remaining challenge for paediatric oncology. A retrospective multicenter study from the Polish Pediatric Solid Tumors' Group. Nowotwory 2006;56:517‐62.
Khattab 2008 {published data only}
    1. Khattab TM, Atra AA, Elimam NA, Kassar A, Zayed A, Baothman A. Improved outcome of children with acute myeloid leukemia treated on 2 consecutive protocols. Saudi Medical Journal 2008;29:776‐7. - PubMed
Kinsella 1991 {published data only}
    1. Kinsella TJ, Miser JS, Waller B, Venzon D, Glatstein E, Weaver‐McClure L, et al. Long‐term follow‐up of Ewing's sarcoma of bone treated with combined modality therapy. International Journal Of Radiation Oncology, Biology, Physics 1991;20:389‐95. - PubMed
Kobe 2008 {published data only}
    1. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first‐line chemotherapy in advanced‐stage Hodgkin lymphoma. Blood 2008;112:3989‐94. - PMC - PubMed
Komp 1976 {published data only}
    1. Komp DM, George SL, Falletta J, Land VJ, Starling KA, Humphrey GB, et al. Cyclophosphamide‐asparaginase‐vincristine‐prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia. Cancer 1976;37:1243‐7. - PubMed
Konopka 1989 {published data only}
    1. Konopka L, Pawelski S. Results of three polychemotherapy programs in non‐Hodgkin's lymphomas. Journal of Chemotherapy 1989;1:1259‐62. - PubMed
Kuleva 2008 {published data only}
    1. Kuleva SA, Anishkin MI, Kolygin BA. A comparison of two risk‐adapted regimens of therapy for Hodgkin's disease in children and adolescents. Voprosy Onkologii 2008;54:53‐8. - PubMed
Kurrle 1988 {published data only}
    1. Kurrle E, Ehninger G, Freund M, Heil G, Hoelzer D, Link H, et al. A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia. Blut 1988;56:233‐6. - PubMed
Lager 2006 {published data only}
    1. Lager JJ, Lyden ER, Anderson JR, Pappo AS, Meyer WH, Breitfeld PP. Pooled analysis of phase II window studies in children with contemporary high‐risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Journal of Clinical Oncology 2006;24:3415‐22. - PubMed
Li 2006 {published data only}
    1. Li CK, Chik KW, Ha SY, Lee ACW, Yuen HL, Ling SC, et al. Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL 97 study. Hong Kong Medical Journal 2006;12:33‐9. - PubMed
Lilleyman 1997 {published data only}
    1. Lilleyman JS, Gibson BE, Stevens RF, Will AM, Hann IM, Richards SM, et al. Clearance of marrow infiltration after 1 week of therapy for childhood lymphoblastic leukaemia: clinical importance and the effect of daunorubicin. The Medical Research Council's Working Party on Childhood Leukaemia. British Journal of Haematology 1997;97:603‐6. - PubMed
Lindberg 1977 {published data only}
    1. Lindberg RD, Murphy WK, Benjamin RS, Sinkovics JG, Martin RG, Romsdahl MM, et al. Adjuvant chemotherapy in the treatment of primary soft tissue sarcomas: a preliminary report. Management of Bone and Soft Tissue Tumors. Chicago: Book Medical Publishers, 1977:343‐52.
Link 1986 {published data only}
    1. Link MP, Goorin AM, Miser AW. The effect of adjuvant chemotherapy on relapse‐free survival in patients with osteosarcoma of the extremity. The New England Journal of Medicine 1986;314:1600‐6. - PubMed
Madej 1987 {published data only}
    1. Madej G, Siedlecki P, Meyza J. Preliminary evaluation of the effectiveness of a modified treatment program in patients with malignant testicular neoplasms. Polski Tygodnik Lekarski 1987;42:836‐40. - PubMed
Madon 1985 {published data only}
    1. Madon E, Pastore G, Cordero Di Montezemolo L, Brach del Prever A, Lanino E. Italian multicenter experience in the treatment of neuroblastoma and soft tissue sarcoma. Minerva Pediatrica 1985;37:603‐10. - PubMed
Mahajan 2008 {published data only}
    1. Mahajan A, Woo SY, Kornguth DG, Hughes D, Huh W, Chang EL, et al. Multimodality treatment of osteosarcoma: radiation in a high‐risk cohort. Pediatric Blood and Cancer 2008;50:976‐82. - PubMed
Mahmoud 1993 {published data only}
    1. Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, et al. Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. The New England Journal of Medicine 1993;329:314‐9. - PubMed
Maiakova 1986 {published data only}
    1. Maiakova SA, Makhonova LA. Consolidating chemotherapy in the treatment program of acute lymphoblastic leukemia in children. Vestnik Akademii Meditsinskikh Nauk SSSR 1986:15‐7. - PubMed
Malpas 1974 {published data only}
    1. Malpas J, Mathe G, Hayat M. Comparison of the effects of cytosine arabinoside, cytosine arabinoside and thioguanine, and cytosine arabinoside and daunorubicin in acute myeloid leukemia. Bulletin du Cancer 1974;61:411‐8. - PubMed
Marcus 1987 {published data only}
    1. Marcus RE, Catovsky D, Prentice HG, Newland AC, Chessells JM, Stevens RF, et al. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982‐1985. Haematology and Blood Transfusion 1987;30:346‐51. - PubMed
Matsuzaki 2001 {published data only}
    1. Matsuzaki A, Ishii E, Nagatoshi Y, Eguchi H, Koga H, Yanai F, et al. Long‐term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu‐Yamaguchi Children's Cancer Study Group. International Journal of Hematology 2001;73:369‐77. - PubMed
Maurer 1981 {published data only}
    1. Maurer HM. The Intergroup Rhabdomyosarcoma Study: update, November 1978. National Cancer Institute Monograph 1981;56:61‐8. - PubMed
Meisel 1999 {published data only}
    1. Meisel JA, Guthrie KA, Breslow NE, Donaldson SS, Green DM. Significance and management of computed tomography detected pulmonary nodules: a report from the National Wilms Tumor Study Group. International Journal of Radiation Oncology, Biology, Physics 1999;44:579‐85. - PubMed
Meza 2006 {published data only}
    1. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. Journal of Clinical Oncology 2006;24:3844‐51. - PubMed
Miser 1993 {published data only}
    1. Miser JS, Pritchard DJ, Rock MG, Shives TC, Gilchrist GS, Smithson WA, et al. Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies. Cancer Treatment and Research 1993;62:333‐8. - PubMed
Moricke 2008 {published data only}
    1. Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M, et al. Risk‐adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL‐BFM 95. Blood 2008;111:4477‐89. - PubMed
Muus 1993 {published data only}
    1. Muus P, Donnelly P, Schattenberg A, Linssen P, Minderman H, Dompeling E, et al. Idarubicin‐related side effects in recipients of T‐cell‐depleted allogeneic bone marrow transplants are schedule dependent. Seminars of Oncology 1993;20:47‐52. - PubMed
Nachman 1993 {published data only}
    1. Nachman J, Sather HN, Buckley JD, Gaynon PS, Steinherz PG, Tubergen DG, et al. Young adults 16‐21 years of age at diagnosis entered on Children's Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols: Results of treatment. Cancer 1993;71:3377‐85. - PubMed
Nishimura 1983 {published data only}
    1. Nishimura H, Yamada T, Hagio Y, Inoue T, Tsunawaki A, Yakushiji M, et al. Treatment of advanced ovarian cancer with cis‐dichlorodiammine platinum (CDDP) as single agent or CDDP in combination with adriamycin (ADM). Gan To Kagaku Ryoho 1983;10:938‐43. - PubMed
Ochiai 1993 {published data only}
    1. Ochiai K. Strategy for the ovarian cancer treatment. Japanese Journal of Cancer and Chemotherapy 1993;20:2454‐60. - PubMed
Oh 2006 {published data only}
    1. Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, et al. Nodal marginal zone B‐cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B‐cell lymphoma. Annals of Hematology 2006;85:781‐6. - PubMed
Okamura 1987 {published data only}
    1. Okamura J, Ikuno Y, Yamada S, Tasaka H, Nibu K, Ikeda N, et al. Results of treatment in children with diffuse large cell lymphoma. Rinsho Ketsueki 1987;28:1365‐9. - PubMed
Omura 1985 {published data only}
    1. Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 1985;3:1240‐5. - PubMed
Ortega 1991 {published data only}
    1. Ortega JA, Wharam M, Gehan EA, Ragab AH, Crist W, Webber B, et al. Clinical features and results of therapy for children with paraspinal soft tissue sarcoma: A report of the intergroup Rhabdomyosarcoma study. Journal of Clinical Oncology 1991;9:796‐801. - PubMed
Paulino 1996 {published data only}
    1. Paulino AC, Wilimas J, Marina N, Jones D, Kumar M, Greenwald C, et al. Local control in synchronous bilateral Wilms tumor. International Journal of Radiation Oncology, Biology, Physics 1996;36:541‐8. - PubMed
Paulino 2003 {published data only}
    1. Paulino AC, Bauman N, Simon JH, Nguyen TX, Ritchie JM, Tannous R. Local control of parameningeal rhabdomyosarcoma: outcomes in non‐complete responders to chemoradiation. Medical and Pediatric Oncology 2003;41:118‐22. - PubMed
Pavlovsky 1981 {published data only}
    1. Pavlovsky S. Argentinian Group for the Treatment of Acute Leukemia: our experience in the treatment of acute lymphoblastic leukemias. Sangre 1981;26:845‐54. - PubMed
Pawson 2001 {published data only}
    1. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA, et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG ± Ida) and second allogeneic stem cell transplant. British Journal of Haematology 2001;115:622‐9. - PubMed
Peeters 2009 {published data only}
    1. Peeters J, Meitert J, Paulides M, Beck JD, Langer T. Late effects surveillance system after childhood cancer in Germany, Austria and parts of Switzerland‐update 2009. Strahlentherapie und Onkologie 2009;185 Suppl 2:5‐7. - PubMed
Perez 1981 {published data only}
    1. Perez CA, Tefft M, Nesbit ME Jr, Burgert EO Jr, Vietti TJ, Kissane J, et al. Radiation therapy in the multimodal management of Ewing's sarcoma of bone: report of the Intergroup Ewing's Sarcoma Study. National Cancer Institute Monograph 1981:263‐71. - PubMed
Pfreundschuh 2008 {published data only}
    1. Pfreundschuh M, Zwick C, Zeynalova S, Duhrsen U, Pfluger KH, Vrieling T, et al. Dose‐escalated CHOEP for the treatment of young patients with aggressive non‐Hodgkin's lymphoma: II. Results of the randomized high‐CHOEP trial of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology 2008;19:545‐52. - PubMed
Picci 1997 {published data only}
    1. Picci P, Bacci G, Ferrari S, Mercuri M. Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. Annals of Oncology 1997;8:1107‐15. - PubMed
Pontz 1981 {published data only}
    1. Pontz BF, Gutjahr P. Aggressive cytostatic treatment of osteogenic sarcoma in childhood. Deutsche Medizinische Wochenschrift 1981;106:200‐7. - PubMed
Pratt 1981 {published data only}
    1. Pratt CB, Hustu HO, Kumar AP, Johnson WW, Ransom JL, Howarth CB, et al. Treatment of childhood rhabdomyosarcoma at St. Jude Children's Research Hospital, 1962‐‐78. National Cancer Institute Monograph 1981:93‐101. - PubMed
Pratt 1993 {published data only}
    1. Pratt CB, Meyer WH, Rao BN, Parham DM, Fleming ID. Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990. Cancer Treatment and Research 1993;62:323‐6. - PubMed
Pritchard‐Jones 2011 {published data only}
    1. Pritchard‐Jones K, Graf N, Bergeron C, Camargo B, Heuvel M, Sandstedt B, et al. Doxorubicin can be safely omitted from the treatment of stage II/III, Intermediate risk histology Wilms tumour ‐ Results of the siop WT 2001 randomised trial, on behalf of the SIOP Renal Tumours Study Group. European Journal of Cancer (European Multidisciplinary Cancer Congress). 2011:S284‐5.
Pritchard‐Jones 2012 {published data only}
    1. Pritchard‐Jones K, Moroz V, Vujanic G, Powis M, Walker J, Messahel B, et al. Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial. Annals of Oncology 2012;23(9):2457‐63. - PubMed
Quattrin 1975 {published data only}
    1. Quattrin N, Montuori R, Girolamo R, Cimino R. Our recent therapeutic experiences in acute leukemia. Minerva Medica 1975;66:2538‐45. - PubMed
Rai 1981 {published data only}
    1. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981;58:1203‐12. - PubMed
Rammeloo 2000 {published data only}
    1. Rammeloo LA, Postma A, Sobotka‐Plojhar MA, Bink‐Boelkens MT, Berg A, Veerman AJ, et al. Low‐dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long‐term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Medical and Pediatric Oncology 2000;35:13‐9. - PubMed
Raney 1983 {published data only}
    1. Raney RB Jr, Lawrence W Jr, Maurer HM, Lindberg RD, Newton WA Jr, Ragab AH, et al. Rhabdomyosarcoma of the ear in childhood. A report from the Intergroup Rhabdomyosarcoma Study‐I. Cancer 1983;51:2356‐61. - PubMed
Raney 1987 {published data only}
    1. Raney B, Schnaufer L, Ziegler M, Chatten J, Littman P, Jarrett P. Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958‐1984. Cancer 1987;59:1‐5. - PubMed
Raney 1988 {published data only}
    1. Raney RB Jr, Tefft M, Maurer HM, Ragab AH, Hays DM, Soule EH, et al. Disease patterns and survival rate in children with metastatic soft‐tissue sarcoma. A report from the Intergroup Rhabdomyosarcoma Study (IRS)‐I. Cancer 1988;62:1257‐66. - PubMed
Raney 1990 {published data only}
    1. Raney RB Jr, Crist W, Hays D, Newton W, Ruymann F, Tefft M, et al. Soft tissue sarcoma of the perineal region in childhood. A report from the Intergroup Rhabdomyosarcoma Studies I and II, 1972 through 1984. Cancer 1990;65:2787‐92. - PubMed
Raza 2008 {published data only}
    1. Raza S, Ullah K, Ahmed P, Khan B. Comparison of anthracycline‐based combination chemotherapy with or without all‐trans retinoic acid in acute promyelocytic leukemia. Journal of the College of Physicians and Surgeons‐Pakistan 2008;18:546‐50. - PubMed
Rees 1990 {published data only}
    1. Rees JK, Gray RG. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study. Haematology and Blood Transfusion 1990;33:243‐8. - PubMed
Ritchey 1994 {published data only}
    1. Ritchey ML, Pringle KC, Breslow NE, Takashima J, Moksness J, Zuppan CW, et al. Management and outcome of inoperable Wilms tumor. A report of National Wilms Tumor Study‐3. Annals of Surgery 1994;220:683‐90. - PMC - PubMed
Ritter 1990 {published data only}
    1. Ritter J, Creutzig U, Schellong G. Improved treatment results in the myelocytic subtypes FAB M1‐M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM‐78 and BFM‐83. Haematology and Blood Transfusion 1990;33:185‐92. - PubMed
Roy 2005 {published data only}
    1. Roy A, Bradburn M, Moorman AV, Burrett J, Love S, Kinsey SE, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. British Journal of Haematology 2005;129:35‐44. - PubMed
Sakic 2006 {published data only}
    1. Sakic M, Berbic‐Fazlagic J. Results of treatment with protocols BFM 90 and BFM 95. Medicinski Arhiv 2006;60:369‐72. - PubMed
Sallan 1977 {published data only}
    1. Sallan SE, Camitta BM, Frei E III, Furman L, Leavitt P, Bishop Y, et al. Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): addition of an anthracycline to vincristine and prednisone. Medical and Pediatric Oncology 1977;3:281‐7. - PubMed
Salodof MacNeil 2010 {published data only}
    1. Salodof MacNeil J. MRC AML 15 trial: similar survival rates from multiple regimens. The Oncology Report 2010:26.
Schaison 1992 {published data only}
    1. Schaison G, Sommelet D, Bancillon A, Perel Y, Leblanc T, Bergeron C, et al. Treatment of acute lymphoblastic leukemia French protocol Fralle 83‐87. Leukemia 1992;6 Suppl 2:148‐52. - PubMed
Scherrer 1994 {published data only}
    1. Scherrer R, Bettelheim P, Geissler K, Jager U, Knobl P, Kyrle PA, et al. High efficacy of the German multicenter ALL (GMALL) protocol for treatment of adult acute lymphoblastic leukemia (ALL) ‐ a single‐institution study. Annals of Hematology 1994;69:181‐8. - PubMed
Schmits 2001 {published data only}
    1. Schmits R, Glass B, Trumper L, Pfreundschuh M. Therapeutic strategies for aggressive lymphomas: the trials of the DSHNHL. Annals of Hematology 2001;80 Suppl 3:B77‐B83. - PubMed
Seibel 2008 {published data only}
    1. Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high‐risk acute lymphoblastic leukemia: A report from the children's oncology group. Blood 2008;111:2548‐55. - PMC - PubMed
Silverman 2000 {published data only}
    1. Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Barr RD, et al. Results of Dana‐Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981‐1995). Leukemia 2000;14:2247‐56. - PubMed
Skoczen 2006 {published and unpublished data}
    1. Skoczen S, Balwierz W, Moryl‐Bujakowska A, Pawinska K, Luszczynska A, Balcerska A, et al. Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group. Przeglad Lekarski 2006;63:11‐4. - PubMed
Smithson 1982 {published data only}
    1. Smithson WA, Telander RL, Carney JA. Mesenchymoma of the liver in childhood: five‐year survival after combined‐modality treatment. Journal of Pediatric Surgery 1982;17:70‐2. - PubMed
Sotnikov 1989 {published data only}
    1. Sotnikov VM, Polianskaia AM, Pan'shin GA, Ingberman I, Kaplanskaia IB. Chemoradiation treatment of patients with aggressive non‐Hodgkin's lymphomas in stages I to II of the disease. Terapevticheskii Arkhiv 1989;61:20‐3. - PubMed
Spears 1992 {published data only}
    1. Spears WT, Morphis II JG, Lester SG, Williams SD, Einhorn LH. Brain metastases and testicular tumors: long‐term survival. International Journal of Radiation Oncology, Biology, Physics 1992;22:17‐22. - PubMed
Spreafico 2008 {published data only}
    1. Spreafico F, Bisogno G, Collini P, Jenkner A, Gandola L, D'Angelo P, et al. Treatment of high‐risk relapsed Wilms tumor with dose‐intensive chemotherapy, marrow‐ablative chemotherapy, and autologous hematopoietic stem cell support: experience by the Italian Association of Pediatric Hematology and Oncology. Pediatric Blood and Cancer 2008;51:23‐8. - PubMed
Sramkova 2013 {published data only}
    1. Sramkova L, Sterba J, Hrstkova H, Mihal V, Blazek B, Timr P, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Magazine of European Medical Oncology 2013;6:41‐5.
Stary 2003 {published data only}
    1. Stary J, Gajdos P, Blazek B, Ptoszkova H, Mihal V, Pospisilova D, et al. Improved results in children with acute lymphoblastic leukemia treated with the ALL‐BFM 90 protocol in the Czech Republic. Casopis Lekary Ceskych 2003;142:404‐9. - PubMed
Steinherz 1993 {published data only}
    1. Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan‐Kettering‐New York‐II protocol. Cancer 1993;72:3120‐30. - PubMed
Steinherz 1996 {published data only}
    1. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al. Cytoreduction and prognosis in acute lymphoblastic leukemia‐the importance of early marrow response: report from the Childrens Cancer Group. Journal of Clinical Oncology 1996;14:389‐98. - PubMed
Steinherz 1998 {published data only}
    1. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T‐cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group. Cancer 1998;82:600‐12. - PubMed
Tarella 2001 {published data only}
    1. Tarella C, Cuttica A, Caracciolo D, Zallio F, Ricca I, Bergui L, et al. High‐dose sequential (HDS) chemotherapy for high‐risk non‐Hodgkin's lymphoma: long‐term analysis and future developments. Annals of Hematology 2001;80 Suppl 3:B123‐6. - PubMed
Taylor 2006 {published data only}
    1. Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia & Lymphoma 2006;47:2321‐30. - PubMed
Tefft 1978 {published data only}
    1. Tefft M, Razek A, Perez C, Burgert EO, Gehan EA, Griffin P, et al. Local control and survival related to radiation dose and volume and to chemotherapy in non‐metastatic Ewing's sarcoma of pelvic bones. International Journal of Radiation Oncology, Biology, Physics 1978;4:367‐72. - PubMed
Thirugnanam 2009 {published data only}
    1. Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide‐based regimen. Biology of Blood and Marrow Transplantation 2009;15:1479‐84. - PubMed
Thomas 1988 {published data only}
    1. Thomas PR, Tefft M, D'Angio GJ, Norkool P. Acute toxicities associated with radiation in the second National Wilms' Tumor Study. Journal of Clinical Oncology 1988;6:1694‐8. - PubMed
Toft 2013 {published data only}
    1. Toft N, Birgens H, Abrahamsson J, Bernell P, Griškevičius L, Hallböök H, et al. Risk group assignment differs for children and adults 1‐45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL‐2008 protocol. European Journal of Haematology 2013;90(5):404‐12. - PubMed
Tournade 1993 {published data only}
    1. Tournade MF, Com‐Nougue C, Voute PA, Lemerle J, Kraker J, Delemarre JFM, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' tumor trial and study: A risk‐adapted therapeutic approach in Wilms' tumor. Journal of Clinical Oncology 1993;11:1014‐23. - PubMed
Tsuchiya 1998 {published data only}
    1. Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S, et al. Caffeine‐assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Research 1998;18:657‐6. - PubMed
Van der Does 1988 {published data only}
    1. Does‐van den Berg A, Wering ER, Suciu S, Solbu G, Rammeloo JA, Koning J, et al. Results of treatment of children with acute lymphatic leukemia (ALL) according to the ALL V protocol of the Netherlands Working Group on Leukemia in Children. Tijdschrift voor Kindergeneeskunde 1988;56:61‐6. - PubMed
Vinogradova 2008 {published data only}
    1. Vinogradova I, Lutsenko IN, Kaplanskaia IB, Vorob'ev IA, Samoilova RS, Gorgidze LA, et al. Efficacy of therapy of different variants of anaplastic large T‐cell lymphomas. Terapevticheskii Arkhiv 2008;80:33‐7. - PubMed
Virchis 2004 {published data only}
    1. Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, et al. Fludarabine, cytosine arabinoside, granulocyte‐colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. British Journal of Haematology 2004;124:26‐32. - PubMed
Vora 2010 {published data only}
    1. Vora AJ, Mitchell C, Goulden N, Richards S. UKALL 2003, a randomised trial investigating treatment reduction for children and young adults with minimal residual disease defined low risk acute lymphoblastic leukaema. Blood (ASH Annual Meeting Abstracts). 2010:116 (abstract 496).
Vose 1994 {published data only}
    1. Vose JM, Anderson JR, Bierman PJ, Bast M, Weisenburger D, Chan WC, et al. Comparison of front‐line chemotherapy for aggressive non‐Hodgkin's lymphoma using the CAP‐BOP regimens. The Nebraska Lymphoma Study Group. Seminars in Hematology 1994;31:4‐8. - PubMed
Watts 2002 {published data only}
    1. Watts RG, Hilliard LM, Berkow RL. Tailored chemotherapy for malignant lymphoma arising in the setting of posttransplant lymphoproliferative disorder after solid organ transplantation. Journal of Pediatric Hematology/Oncology 2002;24:622‐6. - PubMed
Weinstein 1992 {published data only}
    1. Weinstein H, Ravindranath Y, Krischer J, Steuber P, Civin C, Gresik M, et al. The impact of early intensive therapy on event‐free survival (EFS) in children with acute myeloid leukemia (AML). Leukemia 1992;6 Suppl 2:52‐4. - PubMed
Wilimas 1988 {published data only}
    1. Wilimas JA, Douglass EC, Lewis S, Fairclough D, Fullen G, Parham D, et al. Reduced therapy for Wilms' tumor: analysis of treatment results from a single institution. Journal of Clinical Oncology 1988;6:1630‐5. - PubMed
Willemze 1982 {published data only}
    1. Willemze R, Haanen C, Dekker A, Sizoo W, Abels J, Tricot G, et al. Results of a multicentre study of the treatment of acute lymphoblastic leukaemia in adolescents and adults (1978‐1981). The Netherlands Journal of Medicine 1982;25:303‐7. - PubMed
Willnow 1986 {published data only}
    1. Willnow U, Lindner H, Rothe K, Kamprad F. The results of a prospective study for treatment of rhabdomyosarcoma in children. Kinderarztliche Praxis 1986;54:661‐7. - PubMed
Zaharia 1986 {published data only}
    1. Zaharia M, Caceres E, Valdivia S, Moran M, Tejada F. Postoperative whole lung irradiation with or without adriamycin in osteogenic sarcoma. International Journal of Radiation Oncology, Biology, Physics 1986;12:907‐10. - PubMed
Zdrahalova 2011 {published data only}
    1. Zdrahalova K, Sedlacek P, Smisek P, Keslova P, Sterba J, Hrstkova H, et al. The relapsed AML 2001/01, 02 study for children with relapsed acute myeloid leukaemia or initially resistant disease has improved outcome [Lecebna studie relapsed AML 2001/01, 02 pro deti s relapsem akutni myeloidni leukemie nebo primarne rezistentni nemoci zlepsila jejich nadeji na vyleceni]. Transfuze a Hematologie Dnes 2011;17(3):113‐21.
Zimmermann 2012 {published data only}
    1. Zimmermann C, Pötschger U, Amann G, Horcher E, Dieckmann K, Lakatos K, et al. Results of children with renal tumors treated in the Austrian‐Hungarian Wilms Tumor Study 1989 and the International Society of Pediatric Oncology (SIOP) 93‐01/GPOH trial in Austria. Magazine of European Medical Oncology 2012;5:289‐95.
Zintl 1987 {published data only}
    1. Zintl F, Plenert W, Malke H. Results of acute lymphoblastic leukemia therapy in childhood with a modified BFM protocol in a multicenter study in the German Democratic Republic. Haematology and Blood Transfusion 1987;30:471‐9. - PubMed
Zittoun 1992 {published data only}
    1. Zittoun R, Liso V, Mandelli F, Rotoli B, Witte T, Gattringer C, et al. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group. Leukemia 1992;6 Suppl 2:76‐7. - PubMed

References to studies awaiting assessment

FRALLE 2000‐A {published data only}
    1. Baruchel A, Auvrignon A, Auclere M‐F, Perel Y, Mechinaud F, Landman‐Parker J, et al. Childhood standard‐risk B‐cell precursor acute lymphoblastic leukemia (SR‐BCP‐ALL): toxicity and efficacy interim results of the FRALLE 2000‐A protocol (O.093). Pediatric Blood and Cancer 2006;47:380.
    1. Cayuela J‐M, Beldjord K, Preudhomme C, Cave H, Eliahou J‐F, Auclerc M‐F, et al. Minimal residual disease (MRD) in childhood standard‐risk B‐cell precursor acute lymphoblastic leukemia (SR‐BCP‐ALL) at the end of induction (EOI) after a three or four drug induction (O.094). Pediatric Blood and Cancer 2006;47:380‐1.
SIOP2001 {published data only}
    1. Pritchard‐Jones K, Graf N, Bergeron C, Camargo B, Heuvel M, Sandstedt B, et al. Doxorubicin can be safely omitted from the treatment of stage II/III, intermediate risk histology Wilms tumour: Results of the SIOP WT 2001 randomised trial. Pediatric Blood and Cancer (Congress of the International Society of Paediatric Oncology). 2011:741.
Von Stackelberg 2011 {published data only}
    1. Stackelberg A, Yamanaka J, Escherich G, Eckert C, Ratei R, Hitzler JK, et al. Conventional reinduction/consolidation‐type therapy versus short course high intensity combination chemotherapy as post‐induction treatment for children with relapsed acute lymphoblastic leukemia. Early results of study ALL‐REZ BFM 2002. Blood (Annual Meeting of the American Society of Hematology). 2011:118 (abstract 871).

References to ongoing studies

COG AHEP0531 {published data only}
    1. Not mentioned. COG AHEP0531. Not mentioned.
NCT00379457 {published data only}
    1. A protocol for nonmetastatic rhabdomyosarcoma [RMS‐2005]. www.controlled‐trials.com.

Additional references

Billingham 1978
    1. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treatment Reports 1978;62:865‐72. - PubMed
Biondi 2000
    1. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000;96:24‐33. - PubMed
Gratias 2008
    1. Gratias EJ, Dome JS. Current and emerging chemotherapy treatment strategies for Wilms tumor in North America. Paediatric Drugs 2008;10:115‐24. - PubMed
Green 2001
    1. Green DM, Grigoriev YA, Nan B, Takashima JR, Norkool PA, D'Angio GJ, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. Journal of Clinical Oncology 2001;19:1926‐34. - PubMed
Green 2004
    1. Green DM. The treatment of stages I‐IV favorable histology Wilms' tumor. Journal of Clinical Oncology 2004;22:1366‐72. - PubMed
Higgins 2005
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3. Chichester (UK): John Wiley & Sons Ltd, 2006.
Higgins 2009
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane‐handbook.org.
Higgins 2011
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kremer 2002a
    1. Kremer LCM, Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline‐induced clinical heart failure in children: a systematic review. Annals of Oncology 2002;13:503‐12. - PubMed
Kremer 2002b
    1. Kremer LCM, Pal HJH, Offringa M, Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Annals of Oncology 2002;13:819‐29. - PubMed
Kremer 2008
    1. Kremer LCM, Dalen EC, Moher D, Caron HN. Cochrane Childhood Cancer Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008, issue 3.
Lachin 2000
    1. Lachin JM. Statistical considerations in the intent‐to‐treat principle. Controlled Clinical Trials 2000;21:167‐89. - PubMed
Lee 1991
    1. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option?. Statistics in Medicine 1991;10:1595‐605. - PubMed
Lefrak 1973
    1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302‐14. - PubMed
Lipshultz 2005
    1. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. Journal of Clinical Oncology 2005;23:2629‐36. - PubMed
Mertens 2001
    1. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME Jr, Ruccione K, et al. Late mortality experience in five‐year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. Journal of Clinical Oncology 2001;19:3163‐72. - PubMed
Messinger 1999
    1. Messinger Y, Uckun FM. A critical risk‐benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia. Leukemia & Lymphoma 1999;34:415‐32. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34. - PubMed
Pieters 2008
    1. Pieters R, Carroll WL. Biology and treatment of acute lymphoblastic leukemia. Pediatric Clinics of North America 2008;55:1‐20. - PubMed
Reulen 2010
    1. Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long‐term cause‐specific mortality among survivors of childhood cancer. JAMA 2010;304:172‐9. - PubMed
Van Dalen 2006
    1. Dalen EC, Pal HJ, Kok WE, Caron HN, Kremer LCM. Clinical heart failure in a cohort of children treated with anthracyclines: a long‐term follow‐up study. European Journal of Cancer 2006;42:3191‐8. - PubMed
Von Hoff 1979
    1. Hoff DD, Layard MW, Basa P, Davis HL Jr, Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin‐induced congestive heart failure. Annals of Internal Medicine 1979;91:710‐7. - PubMed

References to other published versions of this review

Van Dalen 2007
    1. Dalen EC, Caron HN, Kremer LCM. Anthracyclines versus no anthracyclines for childhood cancer. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006647] - DOI
Van Dalen 2009
    1. Dalen EC, Raphaël MF, Caron HN, Kremer LCM. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD006647.pub2] - DOI - PubMed
Van Dalen 2011
    1. Dalen EC, Raphaël MF, Caron HN, Kremer LCM. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD006647.pub3] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources